Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of vulvovaginal candidiasis
3.2.1.2 Availability of over-the-counter medications
3.2.1.3 Increasing focus on women's health
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse effects associated with antifungal medications
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.4.3 Asia Pacific
3.5 Pipeline analysis
3.6 Reimbursement landscape
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Fluconazole
5.3 Clotrimazole
5.4 Miconazole
5.5 Nystatin
5.6 Ketoconazole
5.7 Terbinafine
5.8 Terconazole
5.9 Other drug classes
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Uncomplicated VVC
6.3 Complicated VVC
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Topical
7.4 Intravenous
Chapter 8 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Prescription drugs
8.3 OTC drugs
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies
Chapter 10 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Netherlands
10.3.7 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 South Korea
10.4.6 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 UAE
10.6.4 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Accord Healthcare Ltd.
11.2 Amneal Pharmaceuticals LLC
11.3 Astellas Pharma Inc.
11.4 Basilea Pharmaceutica Ltd.
11.5 Bayer AG
11.6 Bristol-Myers Squibb Company
11.7 Grupo Ferrer Internacional S.A.
11.8 Johnson & Johnson
11.9 Mycovia Pharmaceuticals, Inc.
11.10 Mylan N.V.
11.11 Pfizer, Inc.
11.12 Scynexis, Inc.
11.13 Teva Pharmaceutical Industries Ltd.
11.14 Zydus Cadila
